Related Experiment Video
Updated: Jun 29, 2025

06:26
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
270
Morphologic prognostic factor for thoracoabdominal aortic dilation after acute type A dissection repair.
Yuichiro Kitada1, Homare Okamura1, Hidenari Hasui1
1Department of Cardiovascular Surgery, Nerima Hikarigaoka Hospital, Tokyo, Japan.
Interdisciplinary Cardiovascular and Thoracic Surgery
|April 8, 2024
Summary
The ventral location of the abdominal aorta's true lumen in acute type A aortic dissection is a significant risk factor for later thoraco-abdominal aortic dilation after surgical repair.
Area of Science:
- Cardiovascular Surgery
- Aortic Diseases
- Medical Imaging
Background:
- Late-term aortic dilation after acute type A aortic dissection (aTAAD) repair requires further investigation.
- Understanding risk factors is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the relationship between abdominal aortic true lumen location and thoraco-abdominal aortic dilation post-aTAAD repair.
- To identify prognostic factors for aortic dilation after aTAAD surgery.
Main Methods:
- Retrospective analysis of 49 patients with aTAAD undergoing surgical repair (April 2014 - July 2022).
- Classification into 'ventral' (true lumen on ventral side) and 'dorsal' groups based on renal artery-level morphology.
- Definition of thoraco-abdominal aortic dilation as ≥5 mm expansion on 1-year postoperative CT scans.
Main Results:
- The ventral group (n=22) showed significantly higher rates of thoraco-abdominal aortic dilation (90.9%) compared to the dorsal group (n=27, 51.9%; P=0.009).
- Ventral true lumen location was identified as an independent prognostic factor for post-operative thoraco-abdominal aortic dilation (OR, 6.01; P=0.009).
Conclusions:
- Abdominal aortic true lumen location, specifically the ventral type, may serve as a prognostic indicator for thoraco-abdominal aortic dilation after aTAAD surgical repair.
- This finding aids in risk stratification and personalized follow-up strategies for aTAAD patients.

